Tjalling Bosse

Active 2006–2026

112
Papers
20,679
Citations
69
h-index
109
i10-index

Citations

Citations per year for Tjalling Bosse1994: 2 citations2006: 1 citations2007: 2 citations2008: 3 citations2009: 1 citations2010: 4 citations2011: 6 citations2012: 6 citations2013: 9 citations2014: 16 citations2015: 47 citations2016: 110 citations2017: 93 citations2018: 148 citations2019: 599 citations2020: 919 citations2021: 1,150 citations2022: 1,113 citations2023: 1,038 citations2024: 1,626 citations2025: 666 citations2026: 17 citations1995–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,238 citing papers, 17.7% of this breakdownChina: 968 citing papers, 13.9% of this breakdownItaly: 619 citing papers, 8.9% of this breakdownUnited Kingdom: 431 citing papers, 6.2% of this breakdownNetherlands: 409 citing papers, 5.9% of this breakdownCanada: 297 citing papers, 4.3% of this breakdownSpain: 283 citing papers, 4.1% of this breakdownGermany: 274 citing papers, 3.9% of this breakdownFrance: 267 citing papers, 3.8% of this breakdownJapan: 192 citing papers, 2.7% of this breakdownAustralia: 149 citing papers, 2.1% of this breakdownSwitzerland: 148 citing papers, 2.1% of this breakdown
0%17.7%Other 24.4%

Fields

  • Medicine74.7%
  • Biochemistry, Genetics and Molecular Biology15.8%
  • Immunology and Microbiology3.4%
  • Engineering3.1%
  • Computer Science1.5%
  • Neuroscience0.3%
  • Other1.2%

Topics

  • Endometrial and Cervical Cancer Treatments11.9%
  • Ovarian cancer diagnosis and treatment5.5%
  • Cancer Immunotherapy and Biomarkers5.4%
  • Genetic factors in colorectal cancer4.9%
  • Cancer Genomics and Diagnostics4.1%
  • Cancer Cells and Metastasis3.2%
  • Other65%

Coauthors

All papers

Open in search
  1. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2020 cited by 1,933

  2. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans Clevers - Nature Medicine 2019 cited by 839

  3. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

    Authors: , , , , , , , , , , - Annals of Oncology 2019 cited by 1,054

  4. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , - Annals of Oncology 2022 cited by 638

  5. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 837

  6. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

    Authors: , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 858

  7. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Kurzeder, Sigurd Lax, Fabrice Lécuru, Jonathan A. Ledermann, Tally Levy, Domenica Lorusso, Johanna Mäenpää, Christian Marth, Xavier Matías‐Guiu, Philippe Morice, Hans W. Nijman, Remi A. Nout, Melanie Powell, Denis Querleu, Mansoor Raza Mirza, Nicholas Reed, Alexandros Rodolakis, Helga B. Salvesen, Jalid Sehouli, Cristiana Sessa, Alexandra Taylor, Anneke M. Westermann, Alain G. Zeimet - Annals of Oncology 2015 cited by 1,380

  8. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas

    Authors: , , , , , , , , , , , , , , , , , , - The Journal of Pathology 2019 cited by 402

  9. Interpretation of somatic POLE mutations in endometrial carcinoma

    Authors: , , , , , , , , , , , , - The Journal of Pathology 2019 cited by 392

  10. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

    Authors: , , , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2023 cited by 162

  11. A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

    Authors: , , , , , , , , , , , , , , , , , , - Cancer Immunology Research 2019 cited by 262

  12. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies

    Authors: , , , , , , , - The Journal of Pathology 2019 cited by 298

  13. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Digital Health 2022 cited by 124

  14. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carien L. Creutzberg, Hans W. Nijman, Tjalling Bosse, Marco de Bruyn - Nature Communications 2022 cited by 144

  15. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups

    Authors: , , , , , , , , , , , , , , , , - The American Journal of Surgical Pathology 2018 cited by 342

  16. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emma J. Crosbie, Richard J. Edmondson, David N. Church, Alexandra Léary, Linda Mileshkin, Pamela M. Pollock, Helen Mackay - Modern Pathology 2022 cited by 161

  17. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials

    Authors: , , , , , , , , , - European Journal of Cancer 2015 cited by 430

  18. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - International Journal of Gynecological Cancer 2020 cited by 248

  19. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

    Authors: , , , , , , , , , , , , , , - Modern Pathology 2015 cited by 490

  20. Practical guidance for mismatch repair-deficiency testing in endometrial cancer

    Authors: , , , , , , , , , , - Annals of Oncology 2016 cited by 346

  21. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cancer 2021 cited by 156

  22. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

    Authors: , , , , , , , , , , - International Journal of Gynecological Cancer 2015 cited by 757

  23. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

    Authors: , , , , - International Journal of Gynecological Cancer 2020 cited by 199

  24. Incorporation of molecular characteristics into endometrial cancer management

    Authors: , , , - Histopathology 2019 cited by 299